Pipeline

PRODUCT NAME
INDICATION
  • PRECLINICAL
  • PHASE I
  • PHASE II
  • PHASE III
  • MARKET
PHASE
PRODUCT NAME
IND
  • PRE
  • PH I
  • PH II
  • PH III
  • MKT
PHASE

Independent Development Programs

Samatasvir (NS5A Inhibitor)

HCV

Phase II

Samatasvir is an NS5A inhibitor which has demonstrated favorable safety and potent pan-genotypic activity in preclinical and clinical studies. Samatasvir is currently being evaluated as part of all-oral combination regimens for up to 12 weeks of treatment.

IDX21437(Uridine nucleotide analog)

HCV

Phase II

IDX21437 is Idenix’s lead next-generation uridine-based nucleotide prodrug which has shown favorable safety and potent, pan-genotypic activity in preclinical studies and in a 7-day monotherapy phase I/II clinical trial.

IDX21459 (Uridine nucleotide analog)

HCV

Phase I

IDX21459 is a follow-on uridine-based nucleotide prodrug currently being evaluated in a phase I clinical trial in healthy volunteers and HCV-infected patients.

Additional Nucleotide Inhibitors

HCV

Preclinical

Idenix maintains robust research programs to identify and develop next-generation nucleotide polymerase prodrugs for HCV with a focus on follow-on nucleotide prodrugs and novel nucleotide prodrugs with complementary resistance profiles to those currently under development.